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Summary
Background High-intensity aerobic exercise might attenuate the symptoms of Parkinson’s disease, but high-quality 
evidence is scarce. Moreover, long-term adherence remains challenging. We aimed to evaluate the effectiveness of 
aerobic exercise—gamified and delivered at home, to promote adherence—on relieving motor symptoms in patients 
with Parkinson’s disease with mild disease severity who were on common treatment regimes.
Methods In this single-centre, double-blind, randomised controlled trial (Park-in-Shape), we recruited sedentary 
patients with Parkinson’s disease from the outpatient clinic at Radboudumc, Nijmegen, Netherlands. Patients were 
made aware of the study either by their treating neurologist or via information in the waiting room. Patients could 
also contact the study team via social media. We included patients aged 30–75 years with a Hoehn and Yahr stage of 
2 or lower, who were on stable dopaminergic medication. Patients were randomly assigned (in a 1:1 ratio) to either 
aerobic exercise done on a stationary home-trainer (aerobic intervention group) or stretching (active control group) by 
means of a web-based system with minimisation for sex and medication status (treated or untreated) and permuted 
blocks of varying sizes of more than two (unknown to study personnel). Patients were only aware of the content of 
their assigned programme. Assessors were unaware of group assignments. Both interventions were home based, 
requiring 30–45 min training three times per week for 6 months. Both groups received a motivational app and remote 
supervision. Home trainers were enhanced with virtual reality software and real-life videos providing a so-called 
exergaming experience (ie, exercise enhanced by gamified elements). The primary outcome was the between-group 
difference in the Movement Disorders Society—Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) motor 
section at 6 months, tested during the off state (≥12 h after last dopaminergic medication). The analysis was done on 
an intention-to-treat basis in patients who completed the follow-up assessment, regardless of whether they completed 
the assigned intervention. Patients reported adverse events directly to their coach and also after the 6-month visit 
retrospectively. A between-group difference of 3·5 points or more was deemed a-priori clinically relevant. The study 
is concluded and registered with the Dutch Trial Registry, NTR4743.
Findings Between Feb 2, 2015, and Oct 27, 2017, 139 patients were assessed for eligibility in person, of whom 130 were 
randomly assigned to either the aerobic intervention group (n=65) or the active control group (n=65). Data from 
125 (96%) patients were available for the primary analysis; five patients were lost to follow-up (four in the intervention 
group; one in the control group). 20 patients (ten in each group) did not complete their assigned programme. The 
off-state MDS-UPDRS motor score revealed a between-group difference of 4·2 points (95% CI 1·6–6·9, p=0·0020) in 
favour of aerobic exercise (mean 1·3 points [SE 1·8] in the intervention group and 5·6 points [SE 1·9] for the control 
group). 11 patients had potentially related adverse events (seven [11%] in the intervention group, four [6%] in the 
control group) and seven had unrelated serious adverse events (three in the intervention group [vestibilar disorder, 
vasovagal collapse, knee injury during gardening that required surgery; 6%], four in the control group [supraventricular 
tachycardia, hip fracture, fall related injury, severe dyskinesias after suprathreshold dose levodopa in a patient with 
deep brain stimulation; 7%]).
Interpretation Aerobic exercise can be done at home by patients with Parkinson’s disease with mild disease severity 
and it attenuates off-state motor signs. Future studies should establish long-term effectiveness and possible disease-
modifying effects.
Funding Netherlands Organization for Health Research and Development.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Introduction
Parkinson’s disease is a progressive neurodegenerative 
dis order.1 Pharmacotherapy alleviates symptoms but is 
limited by response fluctuations with disease progression.2 
Non-pharmacological approaches might offer additi-
onal symptomatic relief. High-intensity aerobic exercise 
appears to be promising with beneficial effects on several 
functional outcomes (that were often specifically trained 
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with the intervention) and physical fitness.3–8 However, 
these studies showed no effect on specific Parkinson’s 
disease signs or Parkinson’s disease severity.9,10 A dose-
finding treadmill study (SPARX trial),11 which was 
specifically powered to find an effect on Parkinson’s dis-
ease severity, showed that high-intensity aerobic exercise 
attenuated Parkinson’s disease motor signs in de-novo 
unmedicated patients. Whether these results can also be 
reached with different types of exercise, in a more 
pragmatic home-based setting that is easier to implement 
and within a broader patient population entailing some-
what more severely affected patients on medication, 
remains to be shown.
It is challenging for patients with Parkinson’s disease to 
adhere to exercise programmes for extended periods. Pro-
vid ing supervision and making exercise more engaging 
and accessible could improve adherence. We designed 
the Park-in-Shape intervention, which incorporates gam-
ing elements (to engage patients) and allows patients to 
exercise at home (cycling on a stationary home-trainer), 
with remote supervision by professional trainers and 
social support from near coaches.12 We report the outcome 
of a randomised controlled, assessor-blinded and patient-
blinded, single-centre study comparing this intervention 
with a non-aerobic active control intervention. Our prim-
ary aim was to evaluate the effect of home-based high-
intensity aerobic exer cise on motor signs of Parkinson’s 
disease (tested off dopaminergic medication) in patients 
with mild disease severity who were on common treat-
ment regimens. The aim of this analysis was to confirm 
and extend the results of the previously published SPARX 
trial to a broader patient population, a different type of 
exercise, and a more pragmatic setting.
Methods
Study design and participants
The Park-in-Shape trial is a single-centre, double-blind, 
home-based, randomised controlled trial comparing aero-
bic exercise with a non-aerobic intervention. Both groups 
received coaching and a specifically designed motivational 
app to enhance engagement and increase compliance.12 
The trial protocol was approved by the medical ethical 
committee Arnhem-Nijmegen. Assess ments were done 
at the Radboudumc Department of Neurology Center of 
Expertise for Parkinson and Movement Disorders, 
Nijmegen. The intervention in both groups was delivered 
in the patients’ homes, with remote supervision by a 
coach (physical therapists or research assistant).
The full protocol, including detailed descriptions of the 
intervention and statistical analysis plan, has been 
published previously.12 The trial protocol is available in 
the appendix (pp 1–86).
Patients with mild Parkinson’s disease (Hoehn and Yahr 
stage ≤2) were eligible for inclusion if, in everyday life, 
they did less than the recommended aerobic exercise for 
older adults (ie, vigorous exercise done <3 times per week, 
Research in Context
Evidence before this study
We searched for randomised controlled studies on aerobic 
exercise and Parkinson’s disease published in MEDLINE up to 
Mar 21, 2019, using comprehensive electronic search strategies 
combining terms “aerobic exercise”, “exercise”, “physical 
therapy”, “physiotherapy”, “endurance training”, “cardiovascular 
training”, “walking”, “cycling”, “bicycling”, “treadmill”, 
“ergometry”, “Parkinson disease”, Parkinson’s disease”, without 
language restrictions. We included studies evaluating exercise 
interventions that lasted at least 4 weeks, that were primarily or 
solely aerobic in nature (as indicated by either target heart 
rates) and that compared aerobic exercise with non-aerobic 
exercise or no exercise.
Evidence from animal studies indicates that high-intensity 
exercise might offer relief of Parkinson motor symptoms 
through adaptive neuroplasticity. We identified 16 studies in 
Parkinson’s disease patients evaluating the clinical effects of 
aerobic exercise; almost half of these were published in the past 
2 years. The Movement Disorders Society—Unified Parkinson’s 
Disease Rating Scale, a validated score for Parkinson’s disease 
severity, was used as primary or secondary outcome in ten of 
these studies. So far, the evidence is inconclusive because of 
conflicting results. Also, previous studies had methodological 
shortcomings such as small sample sizes, lack of masking, and 
improper randomisation methods. Two feasibility trials (both 
published in 2018) were of higher quality, reporting similar 
beneficial effects on attenuation of motor signs, but these 
findings need further confirmation. A major challenge remains 
how the possible beneficial effects of aerobic exercise can be 
implemented in the patients’ own home environment. Only 
one previous study evaluated a home-based aerobic exercise 
programme in a randomised controlled trial. Compliance in 
most earlier studies depended on intensive supervision rates, 
limiting a wider implementation.
Added value of the study
To our knowledge, this is one of the largest high-quality aerobic 
exercise studies in Parkinson’s disease. The results add to 
previous work because of the new setting (fully home-based 
vs highly supervised fitness facility in earlier work), the 
double-blind design, and the unique motivational programme, 
with only minimal and almost exclusively remote supervision, 
versus a more intense and direct supervision scheme in earlier 
work. This multifaceted home-based approach has good 
potential for a wider implementation with good long-term 
adherence.
Implications of all available evidence
Aerobic exercise, even when done at home, is a valuable 
non-pharmacological treatment for patients with Parkinson’s 
disease with mild disease severity.
See Online for appendix
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20 min per session; or moderate exercise done <5 times 
per week, 30 min per session),13 were aged 30–75 years, 
and were on stable dopaminergic pharmacotherapy 
(stable dose for at least 1 month) or were still without 
treatment and expected not to start treatment within the 
next month. We excluded patients on beta-blocking agents 
or antipsychotics; patients with neurological, orthopaedic, 
or cardiac comorbidities that make them unfit to do 
aerobic or stretching exercises; patients with psychiatric 
diseases diagnosed in the past year by a psychiatrist; 
patients with dementia; patients who were unable to 
complete questionnaires after dementia (Mini-Mental 
State Examination score <24) or perform a computer task; 
patients without internet access at home; and patients 
who were unavailable for more than 10% of the study 
period. Changes in medication and deep brain stimula-
tion settings during participation were discouraged but 
allowed at the discretion of the treating physician, creating 
a realistic real-life clinical setting. All patients provided 
written informed consent.
Patients who visited the outpatient clinic of the 
Radboudumc were made aware of the study either by their 
treating neurologist or via information in the waiting 
room. Patients could also contact the study team via social 
media. Eligibility was established through telephone 
screen ing followed by in-person assessments. During 
telephone screen ing, a trained research nurse interviewed 
the patients regarding their physical activity (aerobic sports 
activities were assessed with the sports activities section of 
the Longitudinal Aging Study Amsterdam physical activity 
questionnaire), comorbidity, medication use, ability to 
com plete question naires or perform computer tasks, and 
facilities at home and availability. If there was no reason 
for exclusion at this stage, participants were invited to the 
study site for an additional face-to-face screening. The face-
to-face screen ing was combined with the baseline assess-
ment to minimise the number of study visits. At the 
beginning of the day, patients were tested in a standardised 
off state (12 h since last dopaminergic medication and, if 
applicable, deep brain stimulation switched off during 
measurements). At this timepoint, they were screened for 
dementia (Mini-Mental State Examination score <24) and 
Parkinson’s disease severity. When this was unremark able, 
the additional outcomes as outlined below were assessed 
in the off state. 1 h after ingestion of a suprathreshold dose 
of levodopa (125% of their morning levodopa equivalent 
dose), we did assessments in the on state including 
a graded maximal aerobic exercise test supervised by a 
cardiologist or sports medicine physician (to exclude 
contraindications for aerobic exercise).
All patients provided written informed consent at the 
beginning of the face-to-face test day (eg, before screening 
tests).
Randomisation and masking
Eligible patients were randomly assigned (in a 1:1 ratio) to 
either aerobic exercise (aerobic intervention group) or 
stretching (active control group) by means of a web-based 
system with minimisation for sex and medication status 
(treated or untreated) and permuted blocks of varying 
sizes of more than two (unknown to study personnel). 
The system was created by an independent statistician 
and randomisation was done by a study personnel 
member who was not involved in patient recruitment or 
assessment or data analysis. Patients were unaware of the 
content of either treatment group before participation. 
After random isation, they were only informed about the 
content of their allocated programme by their coach, 
remaining unaware of the intervention in the other 
group). Patient information stated that the study purpose 
was to evaluate the effects of exercise on Parkinson’s 
disease symptoms by comparing two home-based exer-
cise programmes, without specifying that one of the 
programmes was considered a control intervention. 
Information about the details of both programmes was 
not provided except for similarities across both groups 
(coaching, motivational app, home-based exercise three 
times per week). Both programmes were personalised to 
the patient’s abilities to ensure all eligible patients could 
complete the programme. Researchers who assessed 
outcomes or did data analyses were masked to group 
allocation. Patients were instructed not to talk about the 
content of their exercise pro gramme during the post-
intervention visit and could contact their coach in case of 
any problems during trial participation.
Procedures
The aerobic exercise group was instructed to cycle on a 
stationary home-trainer for 30–45 min (30 min aerobic 
and 15 min warming up and cooling down) at least three 
times per week, within a predetermined heart rate zone 
on the basis of their heart rate reserve (HRR; difference 
between resting heart rate and maximal heart rate).14 We 
opted for cycling because this type of exercise is typically 
well preserved in patients with Parkinson’s disease, even 
in those with severe walking difficulties,15,16 and has a low 
risk of falling when patients exercise at home without 
physical supervision. The home-trainer was enhanced 
with virtual reality software and real-life videos, creating 
an exergaming experience. Patients were instructed to 
cycle at a target heart rate zone, which was gradually 
increased for goal setting as patients became fitter. Before 
starting the trial, we decided to use a slightly lower 
intensity than specified in our trial protocol at the start of 
the intervention to allow the patients to get used to the 
equipment as well as the intensity. This change was 
specified explicitly in the publication of our study design.11 
The lower boundary of the target heart rate zone was 
set between 50% and 70% of HRR and was gradually 
increased as patients became fitter during the trial; the 
upper boundary was set at 80% of HRR. Training heart 
rate was registered with a chest-bound heart rate monitor 
and visualised to patients on the connected computer 
screen for direct feedback.
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The active control group was instructed to do stretching, 
flexibility, and relaxation exercises (strength, balance, 
aero bic, and functional components were excluded) 
three times per week for 30 min per session. These exer-
cises were selected from several physiotherapy pro-
grammes designed for patients with Parkinson’s disease.
Patients in both groups received a customised tablet-
based motivational app and coaching (one home visit 
and additional remote supervision by telephone). The 
motivational apps were designed specifically for both 
groups to maintain masking, providing similar items 
such as training instructions, tips for optimal training 
effect, support from loved ones via messages, and the 
opportunity to monitor their progress. The coaching was 
done according to a standardised manual in both groups 
and entailed a home visit to instruct the patients on how 
to use the provided equipment, as well as regular phone 
calls (every fortnight) to evaluate whether the interven-
tion required adjustments on the basis of both the 
patient’s experience and the objective training data. 
There were three coaches who supervised both groups. 
The interventions lasted 6 months.
All exercise activities (including training heart rates) 
were saved on the bike’s computer. Controls registered 
their completed exercises in the app by ticking boxes of 
the exercises done. These results were automatically 
uploaded to a secured website that connected with the 
motivational app, allowing patients to view their own 
progress (number of weekly sessions and cumulative 
number of sessions were displayed for both groups, and 
additionally time within heart rate zone and average 
training heart rate for the aerobic exercise group). Coaches 
could also track exercise performance on the website.
Outcomes were assessed at baseline (T0) and after the 
6 months, when the programme was completed (T1). 
Three trained and certified raters assessed all outcomes 
for a single patient in real time. Most patients were 
assessed at both timepoints by the same rater (17 were 
assessed by a different rater at T0 and T1). Patients 
were instructed to report adverse events directly to their 
coach. At the end of the T1 visit, adverse events were also 
rep orted retro spectively. Adverse events occurring during 
the training sessions and any event that could be in any 
way related to the exercise done were considered possibly 
related.
Outcomes
The primary outcome was the between-group difference 
of the motor section score of the sponsored revision of 
the Movement Disorders Society—Unified Parkinson’s 
Disease Rating Scale (MDS-UPDRS)17 at T1, measured in 
a standardised off state (as defined above). The MDS-
UDPRS is the most widely used, well validated clinical 
rating scale for Parkinson’s disease. Also, we assessed the 
MDS-UPDRS motor section at T1 in the subjectively best 
on state and MDS-UPDRS part IV at T1 as secondary 
outcomes. Neither of the other sections of the UPDRS 
(part I: non-motor experiences in daily living and part II: 
motor experiences in daily living) were assessed. Other 
prespecified secondary outcomes12 were the scores at 
T1 on several motor scales (Mini-Balance Evaluation 
Systems test, Timed Up and Go, Six-minute-walk test, 
pegboard and fingertapping, fall frequency) and non-
motor scales (Hamilton Anxiety and Depression Scale, 
sleep section of Scales for Outcomes in Parkinson’s 
disease [SCOPA], Fatigue Severity Scale, gastro intestinal 
section of the SCOPA Autonomic scale, Montreal 
Cognitive Assessment, Trial Making Test, Test of 
Attentional Performance), quality of life (Parkinson’s 
Disease Questionnaire-39), cardio vascular fitness (VO₂ 
max with graded maximal exercise testing), and adher-
ence to the prescribed intervention (appendix pp 87–89). 
All tests, except for the graded maximal exercise test, 
which was used to measure cardiovascular fitness, were 
done in a standardised off state.
Statistical analysis
The power calculation is detailed elsewhere.12 Our study 
was powered to show an effect of aerobic exercise on 
MDS-UPDRS motor scores after 6 months. The mini mal 
clinically important difference on the MDS-UPDRS 
motor score was not yet defined at the time of the 
power calculation (in 2015, a within-group change of 
4·63 was suggested to indicate a relevant worsening and a 
3·25 difference a relevant improvement);18 instead, we 
used data from the UPDRS motor score that indicated 
2·5 as a minimal difference, 5·2 as a moderate, and 
10·8 as a large clinically important difference for 
patients with Parkinson’s disease with moderate disease 
sev erity.19,20 Combining this with unpublished data from 
our previous feasibility study in patients with early 
Parkinson’s disease where a between-group difference of 
5 points was observed at our site (note that the published 
data reflected the combined data from our centre with 
a second site),21 a difference of 3·5 points between 
intervention and active controls on the MDS-UPDRS 
motor score (tested off) was deemed clinically relevant. 
The SD from our feasibility study (9 points) was used and 
our power calculation considered our planned analy sis 
method, by means of an analysis of covariance (ANCOVA) 
in which baseline measurements served as a covariates, 
reducing the needed sample size.22 Taken together, a 
sample size of 65 patients per group was needed to obtain 
a power of 80% and to accommodate an attrition rate 
of 18–20%.
The primary and secondary outcomes were analysed 
with ANCOVA, with group allocation, sex, and treatment 
status as fixed factors and baseline values of the dependent 
variables, age at baseline, Hoehn and Yahr stage at 
baseline, and disease duration as covariates. Analyses 
were done on an intention-to-treat basis in patients 
who completed the follow-up assessment, regardless of 
whether they completed the assigned intervention. 
Missing data for the primary outcome were imputed by 
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means of multiple imputation techniques (five imputed 
datasets, missing at random for reasons unrelated to the 
data). Additionally, a second imputa tion analysis was done 
in which the scenario of missing data not at random was 
tested and delta-adjustment was done assuming a pro-
gression of MDS-UPDRS motor score for patients who 
dropped out. Natural progression over 6 months is estim -
ated at 2–3 points;23 therefore, 3 points were added to the 
imputed dataset for patients who dropped out. Multiple 
imputations done in an ANCOVA model are solely based 
on data from similar patients in the database and not on 
baseline values of the imputed variable. Therefore, we 
additionally did a linear mixed-model analysis with the 
same covariates as in the ANCOVA analysis. Sensitivity 
analyses were also done to assess the influence of inter-
rater varia bility and unmasking of patients. Analyses were 
done with a two-tailed α of 0·05 in IBM SPSS statistics 
version 25.0.
To ascertain the optimal effect of aerobic exercise, an 
additional per-protocol analysis was done including all 
patients who completed the programme. Adherence to 
the programme was analysed according to intention to 
treat. Adherence to the prescribed intensity (heart rate 
zone) was analysed per protocol. This study is registered 
with the Dutch Trial Registry, NTR4743.
The role of the funding source
The sponsor had no role in the design and conduct of 
the study; collection, management, analysis, and inter-
pretation of the data; or in the preparation and submission 
of the manuscript. The first author and the corresponding 
author had full access to all of the data and the final 
responsibility to submit for publication.
Results
Inclusion occurred between Feb 2, 2015, and Oct 27, 2017. 
We screened 429 potential participants by telephone, 
which led to an additional face-to-face screening in 
139 patients. Four individuals declined to participate and 
five met one or more exclusion criteria (figure). In total, 
130 patients were included and randomly assigned to 
either aerobic exercise (n=65) or active control (n=65; 
figure). Five patients were lost to follow-up and therefore 
had no available data for the primary outcome analysis 
(figure). The technical challenges most frequently encoun-
 tered in the intervention group that led to discontinuation 
of the intervention included failure of the Bluetooth 
connection between the heart rate monitor and the bike 
computer and failure of the software on the bikes due to 
incom patibility with updated operating systems owing to 
the long duration of the trial. 20 patients (ten in each 
group) did not complete their allocated exercise pro-
gramme but attended the post-intervention visit after 
6 months and were therefore included in the data 
analy sis (figure). This resulted in a total attrition rate of 
19%: 22% for aerobic exercise and 17% for active controls 
(not significant). After study completion, 112 (93%) of 
120 patients were still unaware of the intervention content 
of the other group.
Baseline characteristics were similar across both groups 
(table 1). The increase in MDS-UPDRS motor score tested 
in the off state between baseline and 6 months was 
significantly smaller in the aerobic exercise group 
(1·3 points) com pared with controls (5·6 points), resulting 
in a between-group adjusted mean difference of 4·2 points 
(95% CI 1·6–6·9; p=0·0020) in favour of aerobic exercise.
Exercise frequency, duration, and intensity are shown 
in table 2. During the 6 months, aerobic exercise was 
done during a mean of 54 sessions (SD 29) and stretching 
during a mean of 60 sessions (SD 28)—corresponding to 
75% and 83% of the expected 72 sessions for each group, 
respectively. Physical fitness improved in the aerobic 
exercise group (within-group change in VO₂ max 
Figure: Trial profile
The primary analysis was done with an intention-to-treat principle, however for the five drop-outs no outcome 
scores were available. The analysis was done in patients who completed the follow-up assessment, regardless of 
whether they completed the assigned intervention. *The acute back problems and the knee pain were deemed 
adverse events that could possibly be related to the exercise programme. †See appendix p 90 for details.
290 excluded
         189 did not meet inclusion criteria
         101 declined to participate
429 assessed for eligibility by telephone
139 assessed for eligibility in person
65 allocated to aerobic intervention
4 lost to follow-up
    1 progressive complaints from 
       pre-existing spinal stenosis
    1 meniscus surgery
    1 assessment in off state was too 
       burdensome
    1 on vacation (unable to attend 
       post-assessment)
10 discontinued intervention 
      5 discouraged by technical challenges†
      3 physical or mental complaints
         2 knee pain*
         1 depression
      2 psychosocial reasons 
          1 divorce
          1 illness of a child
61 included in the primary analysis
65 allocated to active control
1 lost to follow-up owing to hip fracture 
   after fall
10 discontinued intervention
     6 lost motivation
     4 physical or mental complaints
         1 cognitive problems 
         1 acute onset of back problems*
         1 psychosis provoked by cannabidiol 
            (also had chronic back problems) 
          1 inguinal hernia
64 included in the primary analysis
9 excluded
    5 did not meet inclusion criteria
    4 declined to participate
130 randomised
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2·0 mL/kg per min), whereas it decreased in controls 
(−0·4 mL/kg per min), result ing in a between-group 
adjusted mean difference of 2·4 mL/kg per min (95% CI 
1·1–3·7). All other secondary outcomes showed no 
between-group differences (table 3). Medication changes 
were made in both groups without a significant difference 
between the groups (table 3).
27 adverse events occurred in 23 patients in the aero-
bic exercise group and 29 adverse events occurred in 
21 patients in the active control group. Although most 
events were unrelated to the exercise, a potential relation-
ship could not be excluded in seven (11%) patients in the 
aerobic exercise group and four (6%) in the active control 
group. These potentially related events included arthralgia 
or back pain (n=2 [3%] in the aerobic group and n=4 [6%] 
in the control group) or palpitations (n=4 [6%] in the 
aerobic group) and mostly concerned a worsening or 
reoccurrence of a pre-existing condition. For three patients, 
these adverse events were reason to discont inue their 
intervention. There were seven serious adverse events 
(three for aerobic exercise [vestibilar disorder, vasovagal 
collapse, knee injury during garden ing that required 
surgery] and four among active controls [supraventricular 
tachycardia, hip fracture, fall related injury, severe dys-
kinesias after suprathreshold dose levodopa in a patient 
with deep brain stimulation]); all were unrelated to the 
exercise program (table 4; appendix pp 90–91). Two serious 
adverse events resulted in loss to follow-up and 
discontinuation of the intervention (hip fracture after a 
fall in the garden and a knee injury sus tained during 
gardening which required surgery). Results from 
sensitivity analyses are detailed in the appendix (p 90).
Discussion
This double-blind, randomised controlled trial involv-
ing patients with Parkinson’s disease with mild dis-
ease severity shows that a multifaceted aerobic exercise 
Aerobic intervention 
group (n=65)
Active control 
group (n=65)
Frequency
Number of participants at 
different exercise frequencies
≥3 times per week 16 (25%) 24 (37%)
2–3 times per week 35 (54%) 34 (52%)
<2 times per week 14 (22%) 7 (11%)
Median number of sessions per 
week
2·6 (2·0–2·9) 2·8 (2·4–3·1)
Duration
Median number of weeks 
exercised
22 (16–25) 23 (19–25) 
Median time per session, 
h:min:s
0:33:34 
(0:31:28–0:36:38)
NA
Intensity
Median time per session within 
prescribed heart rate zone, 
h:min:s
0:29:11 
(0:27:47–0:30:08)
NA
Mean training heart rate as a 
percentage of heart rate max
76·4% (8·2) NA
Mean training heart rate as a 
percentage of heart rate reserve
57·0 % (9·6) NA
Data are n (%), median (IQR), or mean (SD). Heart rate reserve=difference between 
resting heart rate and maximal heart rate. Results are calculated over the weeks 
that the patients actually did the exercise (ie, excluding weeks in which they were 
unable to exercise because of vacation or illness). Frequency and duration analyses 
include all patients (n=130); intensity is analysed per-protocol and includes only 
patients who completed the aerobic intervention (n=51). NA=not available. 
Table 2: Adherence outcomes
Aerobic intervention 
group (n=65)
Active control 
group (n=65)
Mean age, years 59·3 (8·3) 59·4 (9·3)
Sex
Female 23 (35%) 27 (42%)
Male 42 (65%) 38 (58%)
Body-mass index 25·9 (3·9) 25·6 (4·3)
Years of education 15·1 (4·0) 16·1 (4·5)
Work situation
Paid work 16 (25%) 23 (35%)
Retired 21 (32%) 28 (43%)
(Partially) unemployed 
due to medical issues
20 (31%) 14 (22%)
Unemployed due to other 
reasons
3 (5%) 0
Marital status
Married or cohabiting 55 (85%) 53 (82%)
Single 10 (15%) 12 (18%)
Disease duration, months 
since diagnosis
41 (16–87) 38 (19–81)
Hoehn and Yahr stage in off state
1 4 (6%) 3 (5%)
2 61 (94%) 62 (95%)
Movement Disorders 
Society-Unified Parkinson’s 
Disease Rating Scale-III score 
in off state*
29·5 (15·7) 27·2 (14·8)
Patients on dopaminergic 
therapy
61 (94%) 63 (97%)
Levodopa equivalent dose, 
mg
600 (375–890) 532 (300–838)
Patients with advanced 
therapies†
4 (6%) 2 (3%)
Montreal Cognitive 
Assessment score‡
26·3 (2·2) 26·3 (2·5)
VO2 max , mL/kg per min§ 26·4 (6·6) 26·0 (6·3)
Good cardiovascular 
fitness¶
13 (20%) 17 (26%)
Data are n (%), median (IQR), or mean (SD). *The MDS-UPDRSIII is a composite 
score of 33 items on a 5-point Likert scale scored 0–4 indicating the severity of 
Parkinson’s disease motor symptoms. Higher scores reflect more Parkinson’s 
disease motor symptoms. †All patients with advanced therapy had deep brain 
stimulation. ‡The Montreal Cognitive Assessment is an education-adjusted 
scale of global cognitive functioning with a maximum total score of 30. 
§The VO2 max is the maximal aerobic power in mL oxygen consumed per kg of 
bodyweight per min. ¶Good cardiovascular fitness is based on VO2 max 
reference scores adjusted for age and sex.
Table 1: Characteristics of patients at baseline
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Baseline 6 months Within-group change from 
baseline after 6 months
Between-group difference in change 
from baseline
Aerobic 
intervention  
group (n=65)
Active control 
group (n=65)
Aerobic 
intervention 
group (n=65)
Active 
control  
goup 
(n=65)
Aerobic 
intervention 
group (n=65)
Active 
control 
group (n=65)
Available data p value
Primary outcome
MDS-UPDRS III, motor score in the off state* 29·5 (2·7) 27·2 (2·7) 29·0 (2·5) 31·4 (2·5) 1·3 (1·8) 5·6 (1·9) −4·2 (1·3; −6·9 to −1·6) 0·0020
Secondary outcomes
Physical fitness
VO2 max, mL/kg per min† 26·6 (1·1) 26·3 (1·1) 28·1 (1·2) 25·8 (1·2) 2·0 (0·9) −0·4 (0·9) 2·4 (0·7; 1·1 to 3·7) <0·0001
Motor symptoms
MDS-UPDRS III, motor score in the on state* 19·4 (1·8) 17·4 (1·8) 21·2 (2·0) 20·3 (2·0) 1·5 (0·8) 2·8 (0·8) −1·2 (1·1; −3·4 to 0·9) 0·26
MDS-UPDRS IV, motor complications score* 2·7 (0·6) 3·1 (0·6) 3·3 (0·9) 3·6 (0·9) −0·4 (0·7) −0·4 (0·7) −0·04 (0·5; −1·0 to 0·9) 0·94
Number of falls 4·3 (0·9) 3·0 (0·9) 2·3 (0·9) 4·5 (0·9) −2·1 (3·7) −0·7 (1·8) −1·3 (4·1; −12·8 to 0·1) 0·76
6-min walk test, m 499·4 (18·2) 486·4 (18·2) 510·6 (17·7) 492·8 (17·7) −11·3 (11·8) −15·6 (12·2) 4·3 (8·8; −13·0 to 21·6) 0·62
Timed Up and Go test, s 8·3 (0·5) 8·7 (0·5) 8·2 (0·5) 8·6 (0·5) 0·5 (0·4) 0·7 (0·4) −0·2 (0·3; −0·7 to 0·3) 0·49
Mini-Balance Evaluation Systems Test‡ 24·3 (0·6) 24·2 (0·6) 24·4 (0·6) 24·5 (0·6) 0·5 (0·5) 0·5 (0·5) −0·03 (0·4; −0·7 to 0·7) 0·94
Pegboard test for the most affected side, s§ 19·5 (0·9) 19·6 (0·9) 18·8 (0·7) 19·4 (0·7) −0·4 (0·7) −0·04 (0·7) −0·4 (0·5; −1·4 to 0·6) 0·44
Finger Tapping Test for the most affected 
side, number of cycles§
65·8 (6·4) 72·6 (6·4) 65·7 (6·4) 73·3 (6·4) −4·9 (7·2) −1·6 (7·4) −3·3 (5·3; −13·7 to 7·2) 0·54
Quality of life
Parkinson’s Disease Questionnaire 
39 summary index score¶
24·9 (2·2) 24·0 (2·2) 26·0 (2·3) 26·3 (2·3) −0·2 (1·9) 0·0 (1·9) −0·2 (1·5;−3·2 to 2·8) 0·91
Non-motor symptoms
Hospital Anxiety and Depression Scale 
depression score||
4·2 (0·5) 3·6 (0·5) 4·5 (0·6) 4·2 (0·6) 0·5 (0·6) 0·7 (0·6) −0·3 (0·6; −1·2 to 0·6) 0·55
Hospital Anxiety and Depression Scale 
anxiety score||
4·2 (0·6) 5·2 (0·6) 4·1 (0·5) 4·2 (0·5) 0·05 (0·5) 0·2 (0·5) −0·1 (0·4; −1·0 to 0·7) 0·74
Scales for Outcomes in Parkinson’s Disease—
sleep, day**
3·2 (0·6) 4·1 (0·6) 3·5 (0·6) 3·9 (0·6) 0·1 (0·5) −0·5 (0·5) 0·6 (0·4; −0·3 to 1·4) 0·20
Scales for Outcomes in Parkinson’s Disease—
sleep, night**
4·4 (0·6) 4·6 (0·6) 4·6 (0·6) 4·6 (0·6) −0·1 (0·7) −0·2 (0·7) 0·1 (0·5; −0·9 to 1·1) 0·85
Fatigue Severity Scale scale†† 3·7 (0·2) 3·9 (0·2) 3·7 (0·2) 3·7 (0·2) 0·5 (0·3) 0·4 (0·3) 0·1 (0·2; −0·3 to 0·5) 0·52
Scales for Outcomes in Parkinson’s Disease—
autonomic dysfunction, constipation 
questions‡‡
1·6 (0·3) 1·6 (0·3) 1·6 (0·3) 1·5 (0·3) 0·03 (0·3) −0·1 (0·3) 0·1 (0·2; −0·3 to 0·5) 0·50
Trail Making Test—Part A, s§§ 39·1 (2·9) 40·3 (2·9) 35·5 (2·6) 37·9 (2·6) −5·9 (2·5) −4·0 (2·6) −2·0 (1·8; −5·6 to 1·7) 0·29
Trail Making Test—Part B, s§§ 95·0 (9·3) 92·2 (9·3) 83·8 (9·1) 90·6 (9·1) −13·8 (9·3) −4·0 (9·5) −9·8 (6·7; −23·0 to 3·5) 0·15
Test of Attentional Performance Flexibility—
baseline conditions, median reaction time, 
s¶¶
590·6 (35·0) 586·6 (35·0) 645·5 (25·4) 656·8 
(25·4)
63·3 (31·4) 77·0 (32·9) −13·6 (23·7; −60·7 to 33·4) 0·57
Test of Attentional Performance Flexibility—
alternating conditions, total performance 
index¶¶
−3·5 (2·2) −4·4 (2·2) −3·6 (1·9) −5·6 (1·9) 0·1 (1·9) −0·5 (2·0) 0·5 (1·5; −2·4 to 3·4) 0·71
Cognitive domain score—Flexibility|||| 0·004 (0·2) −0·03 (0·2) 0·01 (0·1) −0·06 (0·1) 0·03 (0·08) -0·05 (0·08) 0·08 (0·06; −0·03 to 0·2) 0·17
Cognitive domain score—Psychomotor 
speed||||
−0·01 (0·1) −0·003 (0·1) 0·3 (0·1) 0·2 (0·1) 0·4 (0·1) 0·4 (0·1) 0·04 (−0·1; −0·1 to 0·2) 0·64
Montreal Cognitive Assessment 26·3 (0·4) 26·3 (0·4) 25·7 (0·5) 25·9 (0·5) −0·3 (0·6) −0·1 (0·6) −0·2 (0·4; −1·0 to 0·7) 0·70
Explanatory variable***
Levodopa equivalent dose, mg 653·7 (75·7) 644·1 (75·7) 696·9 (81·7) 714·7 (81·7) 47·8 (34·7) 71·1 (35·3) −23·3 (24·2; −71·2 to 24·7) 0·34
Data are mean (SE) or mean (SE; 95% CI). p values and 95% CIs for secondary outcomes are not adjusted for multiple comparisons and cannot be used for hypothesis testing or inference. Post-hoc adjustment for 
multiple comparisons of secondary outcomes by means of the Bonferroni method requires a significance level of p<0·002. The displayed mean baseline SEs are the uncorrected values for both groups. 
MDS-UPDRS=Movement Disorders Society—Unified Parkinson’s Disease Rating Scale. *Higher scores reflect greater severity of Parkinson’s disease signs or more complications. †The VO2 max measures maximal 
aerobic power and higher scores reflect better cardiovascular fitness. ‡Higher scores reflect better balance. §Both outcomes are shown for the side that is most affected by their Parkinson’s disease. ¶Higher scores 
correspond with a poorer health-related quality of life. ||Higher scores reflect more symptoms of anxiety and depression. **Higher scores reflect more severe sleep problems and sleepiness. ††Higher scores reflect 
more complaints of fatigue. ‡‡Higher scores reflect more constipation . §§Higher scores reflect poorer performance on executive functioning. ¶¶Higher scores reflect fewer errors and shorter reaction times. 
||||Higher scores reflect better cognitive performance. ***Data included to suggest a reason for the difference in MDS-UPDRS motor score.
Table 3: Primary and secondary outcomes (by intention to treat)
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pro gramme done at home attenuates MDS-UPDRS motor 
scores compared with stretching, flexibility, and relaxation 
exercises. Specifically, the off-state MDS-UPDRS motor 
score showed a between-group difference of 4·2 points in 
favour of aerobic exercise. This difference is similar to 
previous studies that tested institution-based aerobic 
exercise programmes but that required fairly inten-
sive supervision.11,21 For example, in an institution-based 
aerobic exercise trial (SPARX), newly diagnosed and 
unmedicated patients with Parkinson’s disease received 
full supervision during the first 2 weeks and were there-
after supervised at least twice a month.11 By con trast, the 
effect in this trial was achieved by means of a home-based 
exercise programme with minimal remote supervision. 
Nevertheless, adherence to the home-based intervention 
was good. Aerobic exercise frequency was comparable 
with two previous home-based aerobic exercise trials.24,25 
Attrition rates were comparable with prev ious laboratory-
based exercise trials7,8,11 and a (partly) home-based trial.25 
Importantly, our high exercise inten sity10 was similar to 
laboratory-based trials7,8,11 and higher compared with a 
previous (partly) home-based trial,25 underlining the 
feasibility of our multifaceted approach. Active controls 
showed a similarly good compliance as the aerobic 
exercise group, thus reducing the risk of off-protocol 
exercises among patients assigned to the control group.26 
Being able to exercise at home might be an important 
facilitator for prolonged adherence to exercise pro-
grammes and to achieve sustained improvements in 
patient functioning. Besides the home-based setting, we 
added several components to our intervention to increase 
adherence (remote supervision by sports coaches, a moti-
vational app, and gamification of the intervention itself). 
Informed by our successful pilot study,27 the entire package 
was introduced to promote compliance but this itself was 
not the object of study. The specific added value of this 
multifaceted approach over simple home-based exercise 
without motivation and the relative influence of its indi-
vidual components must be established in future studies.
Our results strengthen previous evidence on the bene-
ficial effects of aerobic exercise on Parkinson’s disease 
symptoms. Without valid and reliable biomarkers of 
disease progression, the MDS-UPDRS motor section is 
often used as a proxy. The downside is that this score 
might be contaminated by medication effects,26 especially 
when tested while in the on state. We therefore used a 
standardised off state to score motor signs to better clarify 
how the intervention affected the disease itself and to 
minimise medication confounding. The time between last 
medica tion intake and testing was similar in each group 
and similar for both assessments. Changes in medication 
throughout the trial (expressed as levodopa equivalent 
dose) were similar across both groups, so this is an 
improbable explan ation for the observed between-group 
difference in MDS-UPDRS motor score tested in the off 
state. The attenuated worsening in motor performance 
after aerobic exercise is considered clinically relevant18,28 
and within the range of symptomatic pharma cological 
treatment effects. For example, the effect of levodopa 
initiated in early Parkinson’s disease ranges between 
3·8 and 6·6 points depending on the prescribed dose.29
The present study confirms and extends the results of 
the SPARX study11 to people who are medicated and have 
had deep brain stimulation. This is an important finding 
with high clinical relevance. Increases over time in 
UPDRS motor scores in people with mild disease severity 
are less steep than in de-novo patients with Parkinson’s 
disease,30 making it more difficult to achieve similar 
effects. Whether even more advanced patients will equally 
benefit from our intervention should be investi gated 
further. Additionally, compared with the single-blind 
design with a wait-list control group in the SPARX trial, 
we used a double-blind design with a rigorously monitored 
non-aerobic control group, and this adds to the robustness 
of the observed beneficial effect in our trial. The present 
study also extends the findings from a treadmill to a cycle, 
which is again important. Also, our findings suggest that 
the exercise effects are robust to how target heart rate is 
calculated—by means of HRR in this study versus 
Aerobic 
intervention 
(n=65)
Active 
control 
(n=65)
Adverse events 23 (35%) 21 (32%)
Possibly related to exercise 7 (11%) 4 (6%)
Possibly related to exercise, severity greater 
than mild
1 (2%) 1 (2%)
Most common events 
Arthralgia and back pain 4 (6%) 3 (4%)
Vasovagal reaction during first visit 2 (3%) 2 (3%)
Fall (related injury) 2 (3%) 2 (3%)
Palpitations 4 (6%) 0 
Arrhythmias 0 2 (3%)
Organ systems affected in >5% of participants 
in a single group
Musculoskeletal and connective tissue 
disorders
7 (11%) 8 (12%)
Musculoskeletal and connective tissue 
disorders, severity greater than mild
4 (6%) 2 (3%)
Cardiac disorders 4 (6%) 2 (3%)
Cardiac disorders, severity greater than mild 0 1 (1%)
Nervous system disorders 2 (3%) 5 (8%)
Nervous system disorders, severity greater 
than mild 
2 (3%) 4 (6%)
Serious adverse events
Musculoskeletal 1 (2%) 0
Cardiac disorders 0 1 (2%)*
Nervous system disorders 1 (2%) 0
Injury, poisoning and procedural 
complications 
0 3 (5%)
Ear and labyrinth disorders 1 (2%) 0
Data are n (%). *One patient had two events.
Table 4: Number of patients with adverse events and serious adverse 
events
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percentage of measured maximal heart rate in the SPARX 
study. Finally, the present study confirms and extends the 
results from a highly supervised health-club setting to a 
home-based setting with minimal remote supervision, 
thus increasing external validity. Taken together, there are 
now two studies with sample sizes of greater than 40 
participants, thus building a strong body of evidence for 
the benefits of endurance exercise.
By contrast with the large differences in off scores, 
there was no significant effect in MDS-UPDRS motor 
scores in the on state in favour of aerobic exercise. 
Specifically, exercise afforded only a small attenuation of 
motor symptoms in the on state (a difference of 1·2 points 
on the MDS-UPDRS) and this difference is not clinically 
rele vant. This could be interpreted as a limitation of the 
clinical relevance of exercise, since ideally an effect would 
be observed over and above optimal medication.31 How-
ever, clear effects in the off state are certainly relevant 
from a patient perspective because, with disease pro-
gression, most patients on dopaminergic medication 
will have fluctuations in UPDRS motor scores due to 
the wearing off phenomenon, unpredictable off periods, 
dose failures, and nocturnal off periods (when patients 
regularly have to walk to the bathroom because of 
nycturia). We are uncertain why exercise exerted a 
relatively greater effect on symptoms seen during the 
off phase compared with the on phase. A possible 
explanation is that the symptomatic effects of exercise are 
mediated primarily by restoration of dopaminergic trans-
mission,32 which would be best visible during the off 
phase. Levodopa presumably has a relatively stronger 
effect on dopaminergic transmission, and this would 
then override the smaller dopaminergic effects of exercise 
in the on phase.
Other motor and non-motor symptoms tested in our 
study showed no between-group differences, perhaps 
because baseline values were relatively good (creating a 
possible ceiling effect) or because aerobic exercise alone 
is not able to improve these symptoms. As previously 
suggested, a combination of task-specific exercise, cogni-
tive engagement, and aerobic exercise might be required 
for an effect on functional mobility, as measured with 
tests such as the Timed Up and Go test and Mini-Balance 
Evaluation System Test.33 Previous studies that used task-
specific aerobic training (ie, gait-based exercise) did show 
improvements on these outcomes.4,8 Our intervention 
involved a generic aerobic exercise without specific gait 
or balance training, possibly explaining the lack of effect 
on the secondary motor outcomes. However, two earlier 
cycling studies did show an improvement on the 6-min 
walking test (as measured in the on state),5,34 which is 
probably a reflection of improved physical fitness. The 
discrepancy with our findings might be attributed to 
the fact that their baseline and follow-up scores were 
considerably worse compared with ours, suggesting the 
possibility of a ceiling effect in our relatively mildly 
affected study population.
The absence of effect on several non-motor domains is 
most probably explained by the relatively short duration of 
the intervention tested here, in combination with the good 
baseline values set against the slowly progressive nature 
of Parkinson’s disease. More prolonged interventions and 
larger sample sizes might be required to achieve tangible 
improvements in non-motor domains such as cogni-
tion. We would also expect that a sustained improve-
ment in non-motor domains—which affect quality of life 
considerably—might be needed to achieve a tangible 
improvement in quality of life. Another explanation for 
the absence of change in secondary outcomes is that the 
observed effect on MDS-UPDRS motor score in the off 
state was a coincidental finding, rather than a true effect. 
However, we consider this improbable, given the positive 
results of the SPARX trial (which found a dose-dependent 
effect of aerobic exercise on UPDRS motor scores) and 
considering the excellent treatment compliance (and 
resultant good exercise effort) provided by our partici-
pants, as reflected by their significantly improved physical 
fitness.
We observed a weak but significant correlation between 
the increase in physical fitness (as measured with the 
VO2 max) and the attenuation in MDS-UPDRS motor 
scores tested in the off state, suggesting a genuine effect 
of aerobic exercise on motor signs. The underlying 
mechanisms of exercise-induced brain health benefits are 
still poorly understood but presumably involve angio-
genesis, increased neurotrophic factors, activation of the 
immune system, and improved mitochondrial function. 
These circumstances create an optimal environment 
for neuroplasticity to occur. Parkinson’s disease animal 
studies show enhanced corticostriatal neurotransmission 
and reduced symptomatology after aerobic exercise.32
Masking in non-pharmacological studies is virtually 
impossible because the intervention is obvious to those 
who receive it and sham procedures are usually not 
available. Unequal placebo effects from insufficient or 
absence of masking can seriously threaten trial validity.35 
By with holding information about the exact content of the 
interventions and the hypothesis of our trial, we tried 
to provide the best alternative to a double-blind non-
pharmacological intervention study. Only a few exercise 
trials in Parkinson’s disease have pursued this altern-
ative double-blind methodology before, but with qualified 
success.25 To diminish the effect of unmasking the assess-
ors, the primary outcome was always the first test done 
during follow-up. Patients were unaware of the content of 
the other exercise programme in 93% of cases, providing 
the best masking of trial hypothesis in Parkinson’s disease 
exercise trials so far. Moreover, excluding unmasked 
patients from the analysis resulted in even larger between-
group differences. It is therefore improbable that placebo 
effects explain our findings.
There are risks when prescribing exercise for patients 
with Parkinson’s disease, especially when it is home 
based, strenuous, and with minimal supervision. The 
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main concerns are musculoskeletal injuries, cardiac 
events, and falls. In our trial, only two falls occurred, both 
of which were unrelated to the exercise. However, 
musculoskeletal complaints occurred frequently in both 
exercise programmes (11·5%) but were unrelated to the 
programme in 60% cases and of mild severity in all 
but one patient. These numbers do not seem to differ 
from the healthy older population, although data for 
musculo skeletal complaints from exercise are scarce in 
this popu lation. The thorough cardiac evaluation before 
participation reduced the risk of ischae mic cardiac events 
in our trial; the main cardiac events reported were 
palpitations and arrhythmias. These are not specific to 
the Parkinson’s disease pop ulation and probably reflect 
an age-related risk. Only one patient had an arrhythmia 
that required medical treat ment. Taken together, our 
interv ention can be considered safe for patients with 
Parkinson’s disease of mild severity, with a small and 
acceptable risk of exercise-related injuries.
Our trial has several limitations. First, the use of 
innovative techniques such as motivational apps or exer-
gaming comes with challenges, especially in an older 
population. We used technological innovations to objecti-
vely measure adherence, to motivate patients to exercise, 
and to improve their performance. Occasional technical 
failures discouraged some patients, leading to drop-outs 
(n=5). Second, establishing physical activity levels on the 
basis of questionnaires remains challenging and is not a 
good estimate for physical fitness. We included several 
patients who turned out to have good cardiovascular 
fitness at baseline, introducing a ceiling effect when 
trying to improve VO2 max. Finally, we do not know 
whether the observed effect on motor symptoms persisted 
beyond the intervention because no follow-up assessment 
was done.
In conclusion, the Park-in-Shape trial provides 
level 1 evi dence that aerobic exercise attenuates motor 
symp toms in Parkinson’s disease and improves cardio-
vascular fitness. The good compliance makes this home-
based intervention suitable for further studies with larger 
sample sizes, longer intervention periods, and several 
post-intervention visits, aiming to examine possible 
effects on motor scores while on medication and on non-
motor symptoms and to examine the sustainability of the 
effects. Finally, encouraged by experimental work in 
rodents, which offered preliminary evidence that exercise 
could beneficially alter the neurodegenerative process,32 
future studies could use similar home-based program mes 
to examine possible disease-modifying effects in humans.
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